BR0014408A - Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos - Google Patents
Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmosInfo
- Publication number
- BR0014408A BR0014408A BR0014408-8A BR0014408A BR0014408A BR 0014408 A BR0014408 A BR 0014408A BR 0014408 A BR0014408 A BR 0014408A BR 0014408 A BR0014408 A BR 0014408A
- Authority
- BR
- Brazil
- Prior art keywords
- antigens
- cells
- hsv
- methods
- identifying
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 241000700584 Simplexvirus Species 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 208000009889 Herpes Simplex Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
"ANTìGENOS DO VìRUS DO HERPES SIMPLES IMUNOLOGICAMENTE SIGNIFICATIVOS; E MéTODOS PARA IDENTIFICAçãO E UTILIZAçãO DOS MESMOS". A invenção fornece antígenos de HSV que são úteis para a prevenção e tratamento de infecção por HSV. Descreve-se epítopos confirmados como sendo reconhecidos por células T derivadas de lesões herpéticas. As células T que têm especificidade para os antígenos da invenção demonstraram atividade citóxica contra células carregadas com epítopos de peptídeos codificados de modo viral, e em muitos casos, contra células infectadas com HSV. A identificação de antígenos imunogênicos responsáveis pela especificidade de células T fornece estratégias antivirais, terapêuticas e profiláticas, aperfeiçoadas. As composições que contêm os antígenos ou polinucleotídeos que codificam os antígenos da invenção fornecem vacinas eficazmente direcionadas para prevenção e tratamento de infecção por HSV.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15718199P | 1999-09-30 | 1999-09-30 | |
US20366000P | 2000-05-12 | 2000-05-12 | |
US21810400P | 2000-07-13 | 2000-07-13 | |
PCT/US2000/026663 WO2001023414A2 (en) | 1999-09-30 | 2000-09-28 | Immunologically significant herpes simplex virus antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0014408A true BR0014408A (pt) | 2002-07-02 |
Family
ID=27387973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0014408-8A BR0014408A (pt) | 1999-09-30 | 2000-09-28 | Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos |
Country Status (16)
Country | Link |
---|---|
US (2) | US6413518B1 (pt) |
EP (1) | EP1222281B1 (pt) |
JP (2) | JP2003512305A (pt) |
KR (1) | KR20020048944A (pt) |
CN (1) | CN1376201A (pt) |
AT (1) | ATE345389T1 (pt) |
AU (2) | AU782676B2 (pt) |
BR (1) | BR0014408A (pt) |
CA (1) | CA2379623C (pt) |
DE (1) | DE60031874D1 (pt) |
HK (1) | HK1044799A1 (pt) |
NO (1) | NO20021479L (pt) |
NZ (2) | NZ531980A (pt) |
PL (1) | PL355265A1 (pt) |
TR (1) | TR200200838T2 (pt) |
WO (1) | WO2001023414A2 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9912671A (pt) * | 1998-08-07 | 2001-05-02 | Univ Washington | Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização |
US6821519B2 (en) * | 2000-06-29 | 2004-11-23 | Corixa Corporation | Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
WO2003011893A2 (en) * | 2001-07-31 | 2003-02-13 | University Of Washington | Immunologically significant herpes simplex virus antigens and methods for using same |
EP2011510B1 (en) * | 2002-07-18 | 2011-01-12 | University of Washington | Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments |
JP2006515277A (ja) | 2002-10-29 | 2006-05-25 | コーリー ファーマシューティカル グループ, リミテッド | C型肝炎ウィルス感染の処置および予防に関する方法および製品 |
JP2007505147A (ja) * | 2003-09-12 | 2007-03-08 | アンティジェニクス インコーポレーテッド | 単純ヘルペスウイルス感染の治療および予防用ワクチン |
CN1989410A (zh) * | 2004-05-24 | 2007-06-27 | 贝勒研究院 | 免疫应答评价方法 |
ATE514775T1 (de) | 2006-02-08 | 2011-07-15 | Illumina Cambridge Ltd | Endenmodifikation zur verhinderung einer überrepräsentierung von fragmenten |
CA2658484A1 (en) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions and methods for vaccinating against hsv-2 |
US20100166808A1 (en) * | 2008-11-17 | 2010-07-01 | Giovanni Marco Pauletti | Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands |
US8460674B2 (en) | 2009-02-07 | 2013-06-11 | University Of Washington | HSV-1 epitopes and methods for using same |
EP2408812B1 (en) | 2009-03-17 | 2015-12-16 | CardioVax, LLC | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions |
WO2010115172A2 (en) * | 2009-04-03 | 2010-10-07 | University Of Washington | Antigenic peptide of hsv-2 and methods for using same |
RU2585961C9 (ru) | 2009-05-22 | 2016-12-27 | Дженосеа Биосайенсиз Инк. | Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа |
EP2305277A1 (en) * | 2009-09-18 | 2011-04-06 | Forskarpatent I Syd AB | Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis |
EP2499488A1 (en) | 2009-11-14 | 2012-09-19 | Kuang-Yuh Chyu | Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis |
RU2013126628A (ru) | 2010-11-12 | 2014-12-20 | Седарс-Синаи Медикал Сентер | Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм |
WO2012074725A2 (en) | 2010-11-12 | 2012-06-07 | Cedars-Sinai Medical Center | Immunomodulatory methods and systems for treatment and/or prevention of hypertension |
AU2011336894B2 (en) | 2010-11-24 | 2016-11-17 | Genocea Biosciences, Inc. | Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response |
JP6099573B2 (ja) * | 2011-01-31 | 2017-03-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法 |
CA2885693C (en) | 2011-11-23 | 2020-07-28 | Genocea Biosciences, Inc. | Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response |
EP2850431B1 (en) | 2012-05-16 | 2018-04-18 | Immune Design Corp. | Vaccines for hsv-2 |
US11267871B2 (en) * | 2014-06-26 | 2022-03-08 | Heiselberg ImmunoTherapeutics GmbH | Topical application for an anti-HSV antibody |
JP2018536023A (ja) * | 2015-10-22 | 2018-12-06 | モデルナティーエックス, インコーポレイテッド | 単純ヘルペスウイルスワクチン |
WO2018064232A1 (en) | 2016-09-28 | 2018-04-05 | Genocea Biosciences, Inc. | Methods and compositions for treating herpes |
CA3050299A1 (en) * | 2017-01-20 | 2018-07-26 | Atara Biotherapeutics, Inc. | Methods of treating multiple sclerosis using autologous t cells |
EP4196134A1 (en) * | 2020-08-13 | 2023-06-21 | Rootpath Genomics, Inc. | Compositions and methods for antigen identification |
WO2022212289A1 (en) * | 2021-03-29 | 2022-10-06 | Rational Vaccines, Inc. | Mutant herpesvirus and vaccine compositions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4859587A (en) | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
EP0541692B1 (en) | 1990-08-02 | 1999-05-06 | Chiron Corporation | Herpes simplex virus vp16 vaccines |
CA2090295A1 (en) | 1992-02-03 | 1993-08-04 | Anthony B. Nesburn | Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use |
GB9325496D0 (en) | 1993-12-14 | 1994-02-16 | Smithkline Beecham Biolog | Vaccines |
JPH11510386A (ja) | 1995-07-28 | 1999-09-14 | マリー キュリー キャンサー ケア | 輸送蛋白質およびそれらの使用 |
EP0948508A4 (en) * | 1996-11-04 | 2001-11-07 | Smithkline Beecham Corp | NEW CODING SEQUENCES FOR HERPES SIMPLEX TYPE 2 VIRUS |
CA2291010A1 (en) * | 1997-06-02 | 1998-12-10 | Chiron Corporation | Herpes simplex virus vp22 vaccines and methods of use |
US6169175B1 (en) * | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
AU3102799A (en) * | 1998-03-20 | 1999-10-11 | Genzyme Corporation | Enhanced anti-tumor immunity |
-
2000
- 2000-09-28 CA CA2379623A patent/CA2379623C/en not_active Expired - Fee Related
- 2000-09-28 US US09/672,595 patent/US6413518B1/en not_active Expired - Lifetime
- 2000-09-28 AU AU78364/00A patent/AU782676B2/en not_active Ceased
- 2000-09-28 NZ NZ531980A patent/NZ531980A/en not_active IP Right Cessation
- 2000-09-28 NZ NZ517959A patent/NZ517959A/en not_active IP Right Cessation
- 2000-09-28 KR KR1020027004169A patent/KR20020048944A/ko not_active IP Right Cessation
- 2000-09-28 BR BR0014408-8A patent/BR0014408A/pt not_active Application Discontinuation
- 2000-09-28 EP EP00968457A patent/EP1222281B1/en not_active Expired - Lifetime
- 2000-09-28 DE DE60031874T patent/DE60031874D1/de not_active Expired - Lifetime
- 2000-09-28 JP JP2001526564A patent/JP2003512305A/ja not_active Withdrawn
- 2000-09-28 PL PL00355265A patent/PL355265A1/xx unknown
- 2000-09-28 CN CN00813480A patent/CN1376201A/zh active Pending
- 2000-09-28 AT AT00968457T patent/ATE345389T1/de not_active IP Right Cessation
- 2000-09-28 TR TR2002/00838T patent/TR200200838T2/xx unknown
- 2000-09-28 WO PCT/US2000/026663 patent/WO2001023414A2/en active IP Right Grant
-
2002
- 2002-03-25 NO NO20021479A patent/NO20021479L/no unknown
- 2002-04-05 US US10/117,476 patent/US6962709B2/en not_active Expired - Fee Related
- 2002-09-02 HK HK02106470.4A patent/HK1044799A1/zh unknown
-
2005
- 2005-11-17 AU AU2005234654A patent/AU2005234654B2/en not_active Ceased
-
2012
- 2012-05-30 JP JP2012122841A patent/JP5602188B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2005234654A1 (en) | 2005-12-15 |
DE60031874D1 (de) | 2006-12-28 |
JP2012214478A (ja) | 2012-11-08 |
CN1376201A (zh) | 2002-10-23 |
KR20020048944A (ko) | 2002-06-24 |
EP1222281A2 (en) | 2002-07-17 |
JP5602188B2 (ja) | 2014-10-08 |
NZ531980A (en) | 2005-04-29 |
NO20021479L (no) | 2002-05-03 |
WO2001023414B1 (en) | 2002-02-28 |
US6962709B2 (en) | 2005-11-08 |
NO20021479D0 (no) | 2002-03-25 |
HK1044799A1 (zh) | 2002-11-01 |
ATE345389T1 (de) | 2006-12-15 |
WO2001023414A3 (en) | 2001-11-08 |
CA2379623C (en) | 2014-09-09 |
JP2003512305A (ja) | 2003-04-02 |
US20020155122A1 (en) | 2002-10-24 |
AU7836400A (en) | 2001-04-30 |
TR200200838T2 (tr) | 2002-06-21 |
WO2001023414A2 (en) | 2001-04-05 |
PL355265A1 (en) | 2004-04-05 |
AU782676B2 (en) | 2005-08-18 |
AU2005234654B2 (en) | 2008-04-24 |
NZ517959A (en) | 2004-05-28 |
CA2379623A1 (en) | 2001-04-05 |
US6413518B1 (en) | 2002-07-02 |
EP1222281B1 (en) | 2006-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0014408A (pt) | Antìgenos do vìrus do herpes simples imunologicamente significativos; e métodos para identificação e utilização dos mesmos | |
BR9912671A (pt) | Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização | |
LU93101I2 (fr) | Imlygic-talimogene laherparepvec | |
BR9712366A (pt) | Gene de gd2 do vírus do herpes simples hsv2 isolado, plasmídeo compreendendo o mesmo, e, processos de induzir, em indivíduo, uma resposta imune contra hsv2 gd2, de tratar um indíviduo que está infectado com hsv, e, de prevenir que um indivíduo fique infectado com hsv | |
WO2003011893A3 (en) | Immunologically significant herpes simplex virus antigens and methods for using same | |
BR9912653A (pt) | Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal | |
EP2316479B8 (en) | Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments | |
MX2023012368A (es) | Vacuna de virus. | |
BR0109928A (pt) | Uso de um herpes vìrus atenuado, e, método para estimular uma resposta imune em um indivìduo humano ou animal, ou para tratar ou prevenir uma infecção patogênica ou câncer em um indivìduo humano ou animal | |
AR005750A1 (es) | Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion | |
GB2359083A (en) | Mutant herpes simplex viruses and uses thereof | |
BR0012985A (pt) | Vacina, bactéria, uso da mesma, e composição farmacêutica e métodos de tratamento ou prevenção de doença mediada por hsv em um hospedeiro humano ou animal e de uma infecção viral da mucosa de um hospedeiro humano ou animal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |